Guardant Health

About Guardant Health

Guardant Health is dedicated to conquering cancer with data through precision oncology. Their mission focuses on transforming cancer care by using blood tests to uncover critical insights that enable early cancer detection and personalized treatment, ultimately improving clinical outcomes for patients at all stages of the disease.

Products & Services

Shield™ Blood Test:A blood test designed for cancer screening to detect early signs of cancer.

Guardant Complete(r) Portfolio:A suite of tests for patients with early and advanced-stage cancer to inform treatment decisions.

Guardant Infinity™:A blood test providing insights for oncology care across various stages of cancer.

BioPharma Solutions:Solutions for translational research and biopharma partners to advance cancer care innovations.

Specialties

Precision Oncology Blood-based Cancer Screening Circulating Tumor DNA Analysis Biomarker-driven Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 350000000 MR: - FA: $350.0 million FAN: 350000000	D: 2025-11-05 FD: 2025-11-05	-
2	RT: Public Offering T: - FT: Public Offering	A: 284400000 MR: - FA: approximately $284.4 million FAN: 284400000	D: 2025-11-05 FD: 2025-11-05	4 investors
3	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 300000000 MR: - FA: 300.0 million FAN: 300000000	D: 2025-11-04 FD: 2025-11-04	-
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 250000000 MR: - FA: 250.0 million FAN: 250000000	D: 2025-11-04 FD: 2025-11-04	4 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 90700000 MR: - FA: $90.7 million FAN: 90700000	D: 2023-12-21 FD: 2023-12-21	1 investors
6	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: 250.0 million FAN: 250000000	D: 2023-05-22 FD: 2023-05-22	4 investors
7	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: 350.0 million FAN: 350000000	D: 2023-05-22 FD: 2023-05-22	4 investors

Convertible Senior Notes Latest

2025-11-05

$350.0M

Public Offering 2025-11-05

$284.4M

Convertible Senior Notes 2025-11-04

$300.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Helmy Eltoukhy

Chairman and co-Chief Executive Officer

A

AmirAli Talasaz

Co-Chief Executive Officer

M

Michael Bell

Chief Financial Officer

D

Darya Chudova

Chief Technology Officer

C

Craig Eagle

Chief Medical Officer

C

Chris Freeman

Chief Commercial Officer, Oncology

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

Guardant Health Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised